Answers are grounded in this paper and cite their sources.
Discovery shows potential for SUCNR1 antagonism to enhance cancer immunotherapy outcomes.
as a lead candidate for targeting SUCNR1 but also provides compelling evidence for SUCNR1 antagonism as a potent therapeutic approach in immuno-oncology.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: